Press Releases

Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.

Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®

Wednesday, December 24, 2025

Bioeq AG Bioeq a Swiss biopharmaceutical company and Zydus Lifesciences Limited Zydus an innovationled lifesciences company with an international presence today announced that its wholly owned subsidiary

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Tuesday, December 23, 2025

Samsung Biologics a leading contract development and manufacturing organization CDMO today announced that its wholly owned US subsidiary Samsung Biologics America has entered into a definitive agreement to acquire

Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv

Tuesday, December 23, 2025

Orexo AB announces the signing of an agreement with Dexcel Pharma USA to divest the full rights to Zubsolv buprenorphinenaloxone sublingual tablet CIII for the treatment of opioid use disorder in the US

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

Monday, December 22, 2025

Roche announced today that the US Food and Drug Administration FDA has approved CDxCD bispecific Lunsumio VELO mosunetuzumab as a subcutaneous SC formulation for the treatment of adult patients with relapsed

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Friday, December 19, 2025

Revvity Inctoday announced the introduction of its forthcoming Signals Xynthetica Modelsasa Service MaaS AI offering within the Revvity Signals platform The Signals Xynthetica offering will enable AIaugmented

Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care

Friday, December 19, 2025

Thermo Fisher Scientific Inc the world leader in serving science today announced the enrollment of the first patient in the new PPD CorEvitas Alzheimers Disease Registry Designed as an international

Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy

Thursday, December 18, 2025

Peptinovo Biopharma an Ann Arborbased biotechnology company pioneering targeted cancer therapies through its proprietary PALM nanotechnology today announced a major manufacturing and intellectual property milestone

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Wednesday, December 17, 2025

Vir Biotechnology Inc today announced that the Company has granted Norgine Pharma UK Limited an affiliate of Norgine a leading European specialty pharmaceutical company an exclusive license for the commercial rights

Sino Biological Wins 2025 Scientist.com’s Supplier Recognition Award

Wednesday, December 17, 2025

Sino Biological Inc a global leader in biological reagents and CRO services recently announced that it has been honored with the Supplier Performance Recognition Award by Scientistcom the marketleading digital platform for outsourced RD procurements

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors

Tuesday, December 16, 2025

Pilatus Biosciences Inc a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers today announced that the US Food and Drug Administration FDA